Pharmacy List: US List · International List · Canadian List · Black List | Drug List · Compare Prices
Recent Posts: Past 24 Hours · Past 48 Hours · Past Week
I have a friend who actually knows a doctor who is in the research and development phase with a company to open an OP. According to this doc, he sees no reason, legally, why he couldn't give percocet scrips as long as the patient records are good. Also, he said, provided he completes the DEA three hour course on buprenorphine, he should be able to prescribe it, and maybe even off-label since it is used for chronic pain in Europe (I know though that patient number a single doc can give bup for is 30 though). Does anyone know why, specifically, with reference to statutes and/or actual cases, OP's do not offer CII's? And I don't want some wild 'cause they know they would get shut down' without any references, because looking at the DEA website, that's a bunch of BS, and this doc seems to think so too. As long as they keep good records, keep the quantity prudent, etc. The issue of interstate commerce I understand comes into play. But is that the method the feds would use to shut down an OP offering CII's? They're not considering oxycontin, just percocets or percodans. What do you all think?
Previous
Index
Next
Flat
New OP in R&D phase consider CII's
Edit 
Reply 
Quote 
Re: New OP in R&D phase consider CII's